The following document is designed to give an executive summary of the key points in relation to medicines optimisation arising from NICE guidance.  It highlights some issues CCGs may wish to consider in terms of implementation of the guidance.

• NICE TA325 Nalmefene for reducing alcohol consumption in people with alcohol dependence – summary for commissioners